KMDA — KAMADA LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1567529 ·
Last close
$7.14
Market Cap
$411.94M
52W High
$8.65
52W Low
$6.89
ADV30
36,555
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 45,240,000 | 19,116,000 | 6,953,000 | 4,132,000 | 383,021,000 | 32,922,000 | 123,634,000 |
| Dec 2025 | 44,678,000 | 16,967,000 | 3,551,000 | 3,562,000 | 378,710,000 | 75,469,000 | 109,640,000 |
| Sep 2025 | 47,010,000 | 19,762,000 | 7,816,000 | 5,296,000 | 377,210,000 | 71,997,000 | 111,978,000 |
| Jun 2025 | 44,754,000 | 18,929,000 | 7,071,000 | 7,376,000 | 368,173,000 | 65,985,000 | 108,219,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$25,490,000
Investing CF
$-9,838,000
Financing CF
$-18,345,000
CapEx
$-9,846,000
Dividends Paid
$-11,534,000
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-17,074,000
Inventory
$84,943,000
Receivables
$28,843,000
ST Investments
—
EBIT TTM
$24,331,000
Pretax Income TTM
$23,467,000
Interest Exp TTM
$864,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$181,682,000
EBITDA
$38,910,000
Free Cash Flow
$11,081,875
Enterprise Value
$348,064,992
Total Cash
$73,147,000
Total Debt
$11,641,000
Shares Out
57,694,272
Trailing EPS
$0.35
Book Value
$4.50
ROE
8.0%
ROA
4.2%
Div Yield
3.52%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 180,460,000 | 26,233,000 | 20,198,000 | 378,710,000 | 109,640,000 | — | 25,490,000 |
| Dec 2024 | 160,953,000 | 20,051,000 | 14,462,000 | 372,255,000 | 112,791,000 | — | 47,594,000 |
| Dec 2023 | 142,519,000 | 10,064,000 | 8,284,000 | 354,907,000 | 110,886,000 | — | 4,315,000 |
| Dec 2022 | 129,339,000 | 4,532,000 | -2,321,000 | 322,379,000 | 146,359,000 | — | 28,586,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.61
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OVID | Ovid Therapeutics Inc. | $414.34M | $2.22 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $408.11M | $0.38 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $418.09M | $6.40 | — |
| EVMN | Evommune, Inc. | $405.21M | $11.25 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $403.63M | $7.93 | — |
News headlines (Yahoo Finance, 1h cache)
Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates
2026-07-29 11:30 · Yahoo
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
2026-07-20 11:00 · Yahoo
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
2026-07-13 11:00 · Yahoo
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
2026-06-01 11:00 · Yahoo
Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Growth Amid Shipment Delays
2026-05-13 23:01 · Yahoo
Kamada Ltd. Q1 2026 Earnings Call Summary
2026-05-13 16:48 · Yahoo
Kamada Q1 Earnings Call Highlights
2026-05-13 16:07 · Yahoo
Kamada Q1 2026 Earnings Call: Complete Transcript
2026-05-13 12:59 · Yahoo
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
2026-05-13 11:00 · Yahoo
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
2026-05-06 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.